Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Boyce Burge who wrote (266)	3/23/1998 12:28:00 AM
From: John Metcalf	Respond to of 4474

Boyce, that's part of it. AP 400 is the product licensed from Stanford and Harvard which activates gene expression. AP 420 is Ariad's product which reverses AP 400 (viz., turns gene expression off). AP 430 is also Ariad's and induces apoptosis in the effected cell. In the era of genomics, these may be regarded as the crown jewels of Ariad.

To: Boyce Burge who wrote (266)	3/23/1998 6:48:00 AM
From: SnowShredder	Read Replies (1) \| Respond to of 4474

The inutero gene therapy is a good way of overcoming the current deficiency in the vectors available today. Retroviral vectors have titers that are too low for effective invivo gene therapy. Thus if you in infect a fetus the number of cells to be infected are reduced dramatically, as well as cell division being very active...allowing integration of DNA. Ariad will have competition for being the pioneer in this type of therapy...French Anderson said @ UCLA that he was very interested in being a pioneer in this therapy. I also agree with you that it will be a while before they will be able to collect on this technology. Best of luck, Where'd He Go?